[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]
Fırat Tıp Dergisi
2004, Cilt 9, Sayı 4, Sayfa(lar) 123-126
[ Turkish ] [ Tam Metin ] [ PDF ]
Effect of Atorvastatin Treatment on Serum Paraoxonase-1 Level in Hyperlipidemic Patients
Yusuf ÖZKAN1, Süleyman Serdar KOCA2, Ferit GÜRSU3, Ertuğrul SONKAYA2, Orhan Kürşad POYRAZOĞLU2, Emir DÖNDER2
1 Fırat Üniversitesi Tıp Fakültesi Endokrinoloji ve Metabolizma Hastalıkları Bilim Dalı, ELAZIĞ
2 Fırat Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, ELAZIĞ
3 Fırat Üniversitesi Tıp Fakültesi Endokrinoloji Biyokimya Anabilim Dalı, ELAZIĞ

Introduction: Atherosclerosis-based diseases like coronary artery disease, myocardial infarction and stroke are leading causes of morbidity and mortality. Hyperlipidemia is among the major risk factors of atherosclerotic diseases and results in accelerated atherosclerosis. Paraoxonase-1 (PON1), an antioxidant enzyme, is reported to have a protective role in the atherosclerotic process, by contributing to the protective effect of HDL and preventing the oxidation of LDL cholesterol. Atorvastatin, a member of the class of statins, which are potent lipid-reducers, is widely used in hyperlipidemia. It was shown that PON1 level decreased in dyslipidemia. The studies on the effects of various lipid-reducing agents on PON 1 levels produced conflicting results. In the present study we aimed to examine the effect of atorvastatin treatment on serum PON1 level.

Material and Methods: Sixty hyperlipidemic patients were treated with 10mg/day atorvastatin for 12 weeks. Serum lipids and PON1 levels were examined at the beginning of the study, in the first and third months and then, compared. Results: Twelve-week atorvastatin treatment brought about favorable changes in lipid profile, in consistency with the literature. Basal PON1 value was 186.94±40.13 (unit/L), whereas PON1 values were 205.60±44.79 (unit/L) in the first month and 226.00±40.15 (unit/L) in the third month. Serum PON1 value was observed to have statistically significantly increased in the third month, when compared to basal values.

Conclusion: Atorvastatin treatment increases levels of PON1, which is reported to assume a protective role in atherosclerosis, in addition to producing positive changes in the lipid profile. ©2004, Fırat Üniversitesi, Tıp Fakültesi


[ Turkish ] [ Tam Metin ] [ PDF ]
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]